AZN
AstraZeneca PLC · Healthcare · Drug Manufacturers - General
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 3.19M | $514.55M | n/a | −2 |
| Q2 2026 | 154 | +6 | 584.53M | $109.90B | +11 | −6 |
| Q1 2026 | 151 | +2 | 571.10M | $111.81B | +21 | −20 |
| Q4 2025 | 148 | 0 | 438.95M | $40.35B | +2 | −1 |
| Q3 2025 | 24 | 0 | 219.30M | $16.82B | +1 | −2 |
| Q2 2025 | 22 | -1 | 189.68M | $13.26B | n/a | −1 |
| Q1 2025 | 21 | 0 | 171.06M | $12.57B | n/a | n/a |
| Q4 2024 | 21 | +3 | 174.28M | $11.42B | +3 | n/a |
| Q3 2024 | 17 | -3 | 166.39M | $12.97B | n/a | −3 |
| Q2 2024 | 20 | n/a | 172.48M | $13.45B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 64.94M | n/a | $5.06B | 0.6% | n/c | 1 | SEC ↗ ×2 |
| 2 | PRIMECAP Management ✦ | 42.60M | n/a | $3.32B | 2.4% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 40.57M | n/a | $3.16B | 0.6% | n/c | 1 | SEC ↗ ×8 |
| 4 | Fisher Asset Management ✦ | 9.96M | n/a | $776.47M | 0.3% | n/c | 1 | SEC ↗ |
| 5 | Capital World Investors ✦ | 6.25M | n/a | $487.65M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Soros Fund Management ✦ | 2.45M | n/a | $191.20M | 5.9% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 2.29M | n/a | $178.48M | 0.4% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 617.71K | n/a | $48.17M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Marshall Wace ✦ | 587.36K | n/a | $45.81M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 498.95K | n/a | $38.91M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 492.18K | n/a | $38.38M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 346.47K | n/a | $27.02M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 261.33K | n/a | $20.38M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Bridgewater Associates ✦ | 209.18K | n/a | $16.31M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Dodge & Cox ✦ | 149.78K | n/a | $11.68M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Norges Bank ✦ (passive) | 120.79K | n/a | $9.42M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 57.50K | n/a | $4.48M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 33.35K | n/a | $2.60M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Millennium Management ✦ | 32.65K | n/a | $2.55M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 13.69K | n/a | $1.07M | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,307 holders, 729.50M shares, $139.69B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · See Remarks · 20 sh @ 160.57 · $3,249
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology